



OWKIN

<https://owkin.com>

#FEDERATEDLEARNING
#MEDICALRESEARCH
#MULTIMODALMODELS

VALUE FOR CLIENT

Cutting-edge ML expertise, specifically deep learning on histopathology, radiology images, genomic data, EHR data, and multimodal data integration.

BUSINESS CASE

Augmented medical research: we combine large amounts of medical data with ML technologies to better understand diseases and heterogeneity of treatment.

VALUE FOR USER

Access to real world data to enhance clinical trial design by answering deep questions such as prediction of response to treatment.

INSIGHTS

Owkin has built 70 predictive models, partnered with 17 research institutions, accessed 40 global datasets, and published 15 scientific articles.

DEEP LEARNING TO PREDICT PROGNOSIS IN MESOTHELIOMA

Owkin built a powerful and interpretable predictive model based on Mesopath/Mesobank, a top-tier research cohort of ~3,000 mesothelioma patients. Using Owkin's proprietary CHOWDER technology to extract interpretable features from images, the team discovered new biomarkers predictive of prognosis in collaboration with expert pathologists independently of current histological classification criteria. Owkin developed a model to extract molecular features from histology images, providing a powerful new tool to enhance clinical practice. This research was published in Nature Medicine and is currently being investigated to optimize mesothelioma clinical trials.

VALUE FOR BRAND

XXX

GEOGRAPHIC COVERAGE

EU, US

HQ LOCALIZATION

Paris, Nantes, London, NYC

FOUNDERS

Thomas Clozel, CEO, MD
Gilles Wainrib, CSO, PhD

FUNDINGS

\$74.1 Series A

INVESTORS

NJF Capital, Otium Venture, Cathay Innovation, GV, F-Prime Capital, Eight Roads Ventures, Bpifrance Large Ventures, MACSF Assurance, Plug and Play, Mubadala Capital